巨头赛诺菲:Dupilumab业绩高涨94%;过专利药物迎来黄昏
2023-08-05 22:00
举报
Dupixent(IL-4R a)业绩为16.34亿欧元,同比大增93.8%;Praluent(PCSK9)业绩仅为1.46亿欧元,同比增长18%;波立维Plavix业绩为5....
相关阅读
2021-08-31
2022-12-27
2023-09-30
2022-02-11
2021-11-05
2022-01-03
2021-04-25
2021-09-08
2021-12-11
2023-08-03
2022-01-07
2021-11-17
